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ABSTRACT 
Background: It is important hat drug therapy for juvenile myoclonic epi- 
lepsy (JME), a lifelong disorder requiring long-term therapy, is effective and 
well tolerated with long-term use. Lamotrigine as monotherapy or adjunctive 
therapy has been demonstrated to be effective in reducing the frequency of par- 
tial and generalized seizures in short- and long-term studies in children, adoles- 
cents, adults, and elderly patients with epilepsy, including those with JME. With 
its tolerability profile and spectrum of efficacy, lamotrigine might be an appro- 
priate option for newly diagnosed patients with JME, a possibility that has not 
been empirically assessed. 
Objective: The aim of this study was to assess the efficacy and tolerability 
of lamotrigine monotherapy in patients with newly diagnosed JME. 
Methods: This open-label study was conducted at 18 clinical sites across 
the United States. Patients aged _12 years with newly diagnosed JME and who 
had experienced at least 1 generalized motor seizure since diagnosis but 
were antiepileptic treatment-naive or had received inappropriate treatment 
due to misdiagnosis were enrolled. During the first 8 weeks of the study, 
lamotrigine (25-mg or 100-mg tablets) was introduced (to a maximum dosage 
of 100-500 mg/d, based on instructions in the package insert and clinical re- 
sponse). This dose escalation was followed by a 24-week treatment phase 
during which lamotrigine dose could be adjusted as needed to achieve opti- 
mal clinical benefit. Efficacy end points included the rates of patients with a 
decrease from baseline of at least 50% in the frequency of myoclonic, tonic- 
clonic, and absence seizures; and the rate of patients with mild, moderate, 
or marked improvement from baseline in global clinical status as perceived 
by the investigators. Adverse events were recorded in patient diaries, and 
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diary information was reviewed by study personnel at clinic visits. Results 
were analyzed using descriptive statistics. 
Results: Twenty-nine patients (17 females, 12 males; mean [SD] age, 24.0 
[11.3] years [range, 12-50 years]) were included in the efficacy analysis. During 
the lamotrigine monotherapy treatment period, 58% of patients experienced a 
reduction from baseline of at least 50% in days with myoclonic seizures, and 
56% and 38% of patients experienced a reduction of at least 50% in the frequen- 
cy of generalized tonic-clonic seizures and absence seizures, respectively. At 
week 24 of the monotherapy phase, investigators perceived that 72% of patients 
had shown mild, moderate, or marked improvement in global clinical status 
relative to the start of the study. 
Conclusions: In this study, lamotrigine monotherapy given to patients with 
newly diagnosed JME was associated with a reduction in the frequency of 
seizures and improvement in global clinical status as rated by the investigators. 
Lamotrigine was generally well tolerated. (Curr Ther Res Clin Exp. 2005;66:230- 
237) Copyright © 2005 Excerpta Medica, Inc. 
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INTRODUCTION 
Juvenile myoclonic epilepsy (JME), a lifelong disorder with a typical onset dur- 
ing early adolescence, affects -10% of those with epilepsy (worldwide). 1-3 The 
myoclonic, absence, and generalized tonic-clonic seizures in patients with JMF. 
are often refractory to treatment with older antiepileptic drugs, such as carbama- 
zepine and phenytoin. 2,4 Valproate is currently the preferred initial monotherapy 
for newly diagnosed patients with JME. After an initial trial of valproate, lamo- 
trigine monotherapy is the treatment of choice for JME and other idiopathic 
epilepsies according to a 2001 consensus panel of 45 US epilepsy experts. 5 
Most of the published evidence for first-line use of valproate in JME derives 
from reports of clinical experience before newer therapeutic options such as 
lamotrigine were available. 1,6-s Whereas lamotrigine has broad-spectrum effica- 
cy for partial and generalized seizures including those in patients with JME, s-lG 
it is generally better tolerated than valproate, which can adversely affect repro- 
ductive and endocrine function and is associated with adverse vents such as 
edema, weight gain, and hair loss. 1,5-s,17-19 The incidence of neurologic adverse 
events is lower with lamotrigine than with carbamazepine or phenytoin; lamo- 
trigine has minimal impact on cognitive function; and it is not associated with 
weight gain. 15,19 Given the tolerability profile of lamotrigine compared with val- 
proate, lamotrigine may be an option for newly diagnosed patients with JME. 
In this open-label, multicenter study, the efficacy and tolerability of lamotri- 
gine monotherapy were assessed among patients with newly diagnosed JME 
who, prior to the study, had received no treatment or had received inappropri- 
ate treatment because of misdiagnosis. 
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PATIENTS AND METHODS 
This open-label study was conducted at 18 clinical sites across the United States. 
Inclusion and Exclusion Criteria 
Patients aged _>12 years, weighing at least 25 kg, having newly diagnosed 
JME (supported by documented clinical features and electroencephalography 
[EEG]), and who had experienced at least 1 generalized motor seizure (as 
defined in the International Classification of Seizures 2°) since diagnosis were 
enrolled. Diagnostic features of JME were considered to include a characteris- 
tic EEG pattern of diffuse, bilateral, symmetric, and synchronous polyspike-and- 
wave complexes of 4 to 6 Hz; sudden mild to moderate myoclonic jerks of the 
shoulders and arms that usually occurred after awakening; tonic-clonic, clonic- 
tonic-clonic, and/or absence seizures in addition to myoclonus; and precipi- 
tation by photosensitivity, sleep deprivation, alcohol intake, and/or fatigue. 21 
Prior to the study, these patients had received no treatment or had received 
inappropriate treatment (ie, any medication other than valproate or lamotri- 
gine) because of misdiagnosis. The study also enrolled patients who converted 
to lamotrigine monotherapy because of poor efficacy or tolerability of valpro- 
ate monotherapy. The data from the latter group of patients are reported else- 
where 22 and are not included in this report. 
Patients were excluded from the study if they were perceived by the investi- 
gator to be an inappropriate candidate for therapy with lamotrigine; had used 
any investigational drug within 4 weeks of initiation of the study or had been 
previously exposed to lamotrigine; were being treated with >1 antiepileptic 
drug; were pregnant, breastfeeding, or attempting to become pregnant; adhered 
to a ketogenic diet; had severe organic disease; had a history of alcohol or other 
drug abuse or dependence; had a history of medication noncompliance as 
determined by the investigator; or planned during the study period to undergo 
vagal stimulation or surgery to control seizures. Females were enrolled only if 
they agreed to use an acceptable contraceptive method during the study or 
were incapable of bearing children. All patients or their parents or legal 
guardians provided written informed consent, and institutional review board 
approval of the study protocol was obtained from all study sites. 
Study Phases 
This study comprised 3 phases: (1) a 2-week screening phase, during which 
eligibility was verified and baseline physical and seizure assessments were 
obtained; (2) a dose-escalation phase lasting up to 8 weeks, during which la- 
motrigine (25-mg or 100-mg tablets) was introduced (to a maximum dosage of 
100-500 mg/d, based on instructions in the package insert 23 and clinical re- 
sponse); and (3) a 24-week treatment phase, during which lamotrigine dose 
could be adjusted as needed to achieve optimal clinical benefit. 
During the dose-escalation a d treatment phases, patients or their parents/ 
guardians were to record, in a daily diary provided to them, the number of 
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days on which the patient experienced myoclonus and the number of gener- 
alized tonic-clonic seizures and absence seizures. These measures were ret- 
rospectively determined for the 12 weeks prior to the screening visit to 
obtain baseline values against which to compare the study data. Because of 
the open-label nature of the study, patients who received at least 1 dose of 
study medication but who discontinued the study prematurely were consid- 
ered treatment failures. Adverse events (defined as any untoward medical 
occurrence regardless of its suspected cause) were recorded in patient 
diaries. Clinic visits for the review of diaries, adverse events, and concomi- 
tant medication use occurred during the screening phase and at weeks 1, 12, 
and 24 of the treatment phase. Adverse events were recorded throughout the 
study, beginning on the day after screening. Any serious adverse events that 
were unresolved at the last study visit were followed up until the event 
resolved or stabilized, the patient was lost to follow-up, or the event was oth- 
erwise explained. 
On weeks 1, 12, and 24 of the treatment phase, investigators rated patients' 
global clinical status and their status on the following specific indices: seizure 
frequency, seizure duration, seizure intensity, adverse events, social function- 
ing, intellectual functioning, and motor functioning. Global clinical status was 
rated by investigators as marked, moderate, or mild deterioration; no change; 
or marked, moderate, or mild improvement. At weeks 1, 12, and 24 of the treat- 
ment phase, patients rated their satisfaction with therapy as much better, 
somewhat better, the same as, somewhat worse, or much worse than prestudy 
therapy. Power analysis was not undertaken for this study. 
RESULTS 
Twenty-nine patients (17 females, 12 males; mean [SD] age, 24.0 [11.3] years 
[range, 12-50 years]) received at least 1 dose of lamotrigine. During the treat- 
ment phase, the mean lamotrigine maintenance dosage was 317.6 mg/d (range, 
100-500 mg/d). Nine patients (31%) withdrew prematurely from the study 
(Table). The primary reason for premature discontinuation was adverse vents 
(4 patients [14%]) (discussed later). 
The median monthly frequencies of seizures at baseline in all patients who 
enrolled in the study were 5.0, 0.3, and 8.0 for days with myoclonus, number of 
generalized tonic-clonic seizures, and number of absence seizures, respectively. 
Over the lamotrigine treatment period, 58% of patients experienced a reduc- 
tion from baseline of at least 50% in days with myoclonic seizures, and 56% and 
38% of patients experienced a reduction of at least 50% from baseline in fre- 
quency of generalized tonic-clonic and absence seizures, respectively (Figure). 
Two patients (7%) experienced an increase of >25% from baseline in the fre- 
quency of myoclonus during the treatment phase. 
At week 24 of the treatment phase, investigators perceived that 72% of 
patients had shown mild, moderate, or marked improvement in global clinical 
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Table. Baseline demographic and clinical characteristics of the study 
patients (N = 29). 
Characteristic Value 
Age, y 
Mean (SD) 24.0 (11.3) 
Range 12-50 
Sex, no. (%) 
Female 1 7 (59) 
Male 12 (41) 
Race, no. (%)* 
White 21 (72) 
Black 3 (10) 
Other 5 (1 7) 
Study completers, no. (%) 20 (69) 
Discontinued, no. (%) 9 (31) 
Adverse event 4 (14) 
Lost to follow-up 3 (10) 
Protocol violation 2 (7) 
*Percentages do not total 100 due to rounding. 
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status relative to the start of the study. The rates of patients perceived to be 
mildly, moderately, or markedly improved from baseline on the 7 specific status 
indices were as follows: seizure frequency (69%), seizure intensity (66%), seiz- 
ure duration (62%), social functioning (41%), motor functioning (34%), adverse 
events (31%), and intellectual functioning (31%). 
On their final visit, 92% of patients indicated that they were mildly, moderate- 
ly, or highly satisfied with the study medication. 
In the 29 patients who received at least 1 dose of lamotrigine, adverse vents 
that investigators considered to be at least possibly related to study medication 
were dizziness (5 patients [17%]); headache (4 [14%]); somnolence (3 [10%]); 
amnesia, asthenia, nausea, and vomiting (2 patients [7%] each); and tremor, 
insomnia, cognitive abnormality, emotional lability, confusion, depression, apa- 
thy, nervousness, abdominal pain, dyspepsia, contact dermatitis, leukopenia, 
weight increase, arthralgia, arthritis, myalgia, and rhinitis (1 patient [3%] each). 
Four patients (14%) withdrew from the study prematurely because of ad- 
verse events, including increased generalized seizures, arthralgia/myalgia, coma 
(secondary to drowning after having a sefzure), and viral-like illness (1 patient 
[3%] each). 
DISCUSSION 
In this study, lamotrigine monotherapy given to patients with newly diagnosed 
JME was associated with a reduction in seizure frequency and improvement in 
clinical status as rated by investigators. 
The results of this investigation should be interpreted in the context of its 
limitations, which preclude drawing conclusions about the role of lamotrigine 
in the clinical improvements. First, the study employed an open-label design. 
Therefore, the degree to which improvements can be attributed to study medi- 
cation is uncertain. Second, the sample size of the study was small. Third, the 
study employed retrospective baseline data. Seizure counts from memory may 
be inaccurate and may underestimate or overestimate s izure frequency. De- 
spite these limitations, the data are encouraging in their consistency with 
previous results 8,9,11,14,22 from studies in patients with JME and other idiopathic 
epilepsy syndromes. 2,3 These findings corroborate reports of the efficacy and 
tolerability of lamotrigine in patients with JME converting from valproate ther- 
apy. 8,9,11,14,22 For example, seizures were controlled, and the valproate-associated 
adverse ffects of edema, weight gain, and hair loss were reduced or eliminated 
in 12 patients with JME who switched from valproate to lamotrigine or who added 
lamotrigine to a regimen containing a reduced valproate dose. 8
CONCLUSIONS 
In this open-label study, lamotrigine monotherapy given to patients with newly 
diagnosed JME was associated with a reduction in the frequency of seizures and 
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improvement in global clinical status as rated by the investigators. Lamotrigine 
was generally well tolerated. 
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